Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report

BACKGROUND: MET fusion is a rare type of structure rearrangement, reported only in 0.26% of non-small cell lung cancer (NSCLC). Some uncommon genomic variants, including MET fusions, have been detected with advanced detection technology. Therapeutic option for MET-rearranged NSCLC remains largely un...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Junfang, Shen, Lijun, Qian, Yunyao, Liu, Yunpeng, Su, Minhong, Yi, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459510/
https://www.ncbi.nlm.nih.gov/pubmed/36093550
http://dx.doi.org/10.21037/tcr-22-141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459510/
https://www.ncbi.nlm.nih.gov/pubmed/36093550
http://dx.doi.org/10.21037/tcr-22-141

Ejemplares similares